Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization
Patients hospitalized with an AECOPD and eosinophilic inflammation of greater than 300 cells/μl of blood within the prior 12 months, had no benefit in risk of time to readmission or death following treatment with mepolizumab for 48 weeks. The observed change in moderate or severe exacerbations, which included the null in the upper bound of the 95% confidence interval, was in the direction observed in previous trials. (Funded by GSK plc; ClinicalTrials.gov number, NCT04075331.).
Authors
- Adam Wright (ORCID: https://orcid.org/0000-0003-1621-1622)
- Michael Steiner (ORCID: https://orcid.org/0000-0002-0127-0614)
- Cara Flynn (ORCID: https://orcid.org/0009-0005-9326-966X)
- Hannah R. Gilbert (ORCID: https://orcid.org/0009-0008-0450-9353)
- Cassandra Brookes (ORCID: https://orcid.org/0000-0002-0084-0400)
- Omer Elneima (ORCID: https://orcid.org/0000-0003-2480-8840)
- Vijay Mistry (ORCID: https://orcid.org/0000-0002-3761-4714)
- Wadah Ibrahim (ORCID: https://orcid.org/0000-0001-6404-895X)
- Christopher Edward Brightling (ORCID: https://orcid.org/0000-0002-9345-4903)
- Hamish J. C. McAuley (ORCID: https://orcid.org/0000-0001-8997-0764)
- Michelle Bourne
- Ghazala Waheed (ORCID: https://orcid.org/0000-0002-5142-110X)
- Rachael A Evans (ORCID: https://orcid.org/0000-0002-1667-868X)
- Tracy Thornton
- Neil J. Greening (ORCID: https://orcid.org/0000-0003-0453-7529)
- Tom Ward (ORCID: https://orcid.org/0000-0002-2748-4063)
- Hnin Aung (ORCID: https://orcid.org/0000-0002-5692-3256)
Institutions
- University of Leicester (GB)
- University Hospitals of Leicester NHS Trust (GB)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1056/evidoa2500012
- Citations
- 11
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 16.70